There are multiple methodologies for the testing of measurable residual disease (MRD), which each come with various pros and cons, and are favoured by different parties. Speaking from the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, Christopher Hourigan, MD, DPhil, of the National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, discusses the role of genome-based techniques and flow cytometry for MRD measurement in acute myeloid leukemia (AML). Giving his interesting insights, Dr Hourigan highlights the current utility of both methods, as well as predicting what the future might hold in this area.
Measuring MRD in AML: current landscape and future outlook
